E
Elena Elez
Researcher at Autonomous University of Barcelona
Publications - 44
Citations - 2926
Elena Elez is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Colorectal cancer & Cetuximab. The author has an hindex of 18, co-authored 44 publications receiving 1886 citations.
Papers
More filters
Journal ArticleDOI
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
Susan Bullman,Susan Bullman,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Ewa Sicinska,Thomas E. Clancy,Xiaoyang Zhang,Xiaoyang Zhang,Diana Cai,Diana Cai,Donna Neuberg,Katherine H. Huang,Fatima Guevara,Timothy Nelson,Otari Chipashvili,Timothy Hagan,Mark Walker,Aruna Ramachandran,Aruna Ramachandran,Begoña Diosdado,Begoña Diosdado,Garazi Serna,Nuria Mulet,Stefania Landolfi,Santiago Ramón y Cajal,Roberta Fasani,Andrew J. Aguirre,Andrew J. Aguirre,Andrew J. Aguirre,Kimmie Ng,Elena Elez,Shuji Ogino,Shuji Ogino,Josep Tabernero,Charles S. Fuchs,William C. Hahn,William C. Hahn,William C. Hahn,Paolo Nuciforo,Matthew Meyerson,Matthew Meyerson,Matthew Meyerson +41 more
TL;DR: Col colonization of human colorectal cancers with Fusobacterium and its associated microbiome—including Bacteroides, Selenomonas, and Prevotella species—is maintained in distal metastases, demonstrating microbiome stability between paired primary and metastatic tumors.
Journal ArticleDOI
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study
Eli L. Diamond,Eli L. Diamond,Vivek Subbiah,A. Craig Lockhart,Jean-Yves Blay,Igor Puzanov,Ian Chau,Noopur Raje,Jürgen Wolf,Joseph P. Erinjeri,Jean Torrisi,Mario E. Lacouture,Elena Elez,Ferran Martínez-Valle,Benjamin H. Durham,Maria E. Arcila,Gary A. Ulaner,Omar Abdel-Wahab,Bethany Pitcher,Martina Makrutzki,Todd Riehl,José Baselga,David M. Hyman +22 more
TL;DR: In this study, vemurafenib had prolonged efficacy in patients with BRAF V600–mutant ECD and LCH and warrants consideration as a new standard of care for these patients.
Journal ArticleDOI
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Vivek Subbiah,Ulrik Lassen,Elena Elez,Antoine Italiano,Giuseppe Curigliano,Milind Javle,Filippo de Braud,Gerald W. Prager,Richard Greil,Alexander Stein,Angelica Fasolo,Jan H.M. Schellens,Patrick Y. Wen,Kert Viele,Aislyn Boran,Eduard Gasal,Paul Burgess,Palanichamy Ilankumaran,Zev A. Wainberg +18 more
TL;DR: Dabrafenib plus trametinib combination treatment showed promising activity in patients with BRAFV600E-mutated biliary tract cancer, with a manageable safety profile, based on an interim analysis.
Journal ArticleDOI
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer
Robin M.J.M. van Geel,Josep Tabernero,Elena Elez,Johanna C. Bendell,Anna Spreafico,Martin Schuler,Takayuki Yoshino,Jean Pierre Delord,Yasuhide Yamada,Martijn P. Lolkema,Martijn P. Lolkema,Jason E. Faris,Ferry A.L.M. Eskens,Sunil Sharma,Rona Yaeger,Heinz-Josef Lenz,Zev A. Wainberg,Emin Avsar,Arkendu Chatterjee,Savina Jaeger,Eugene Tan,Kati Maharry,Tim Demuth,Jan H.M. Schellens,Jan H.M. Schellens +24 more
TL;DR: It is demonstrated that dual- and triple- combination treatments are tolerable and provide promising clinical activity in the difficult-to-treat patient population with BRAF-mutant mCRC.
Journal ArticleDOI
Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Anita Sveen,Jarle Bruun,Jarle Bruun,Peter W. Eide,Ina A. Eilertsen,Lorena Ramírez,Astrid Murumägi,Mariliina Arjama,Stine A. Danielsen,Kushtrim Kryeziu,Elena Elez,Josep Tabernero,Justin Guinney,H.G. Palmer,Arild Nesbakken,Arild Nesbakken,Olli Kallioniemi,Rodrigo Dienstmann,Rodrigo Dienstmann,Ragnhild A. Lothe,Ragnhild A. Lothe +20 more
TL;DR: A new, cancer cell–adapted classifier was found to perform well in primary tumors, and applied to a panel of 148 cell lines and 32 PDXs, these colorectal cancer models were shown to recapitulate the biology of the CMS groups.